169 related articles for article (PubMed ID: 37990786)
1. Structure-Based Discovery of A Small Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) that Significantly Reduces Alzheimer's Disease Neuropathology.
Mondal P; Bai P; Gomm A; Bakiasi G; Lin CJ; Wang Y; Choi SH; Tanzi RE; Wang C; Zhang C
Adv Sci (Weinh); 2024 Jan; 11(1):e2304545. PubMed ID: 37990786
[TBL] [Abstract][Full Text] [Related]
2. Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.
Zhang L; Liu C; Wu J; Tao JJ; Sui XL; Yao ZG; Xu YF; Huang L; Zhu H; Sheng SL; Qin C
J Alzheimers Dis; 2014; 41(4):1193-205. PubMed ID: 24844691
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
Li Y; Sang S; Ren W; Pei Y; Bian Y; Chen Y; Sun H
Eur J Med Chem; 2021 Dec; 226():113874. PubMed ID: 34619465
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells.
Asthana J; Kapoor S; Mohan R; Panda D
J Biol Chem; 2013 Aug; 288(31):22516-26. PubMed ID: 23798680
[TBL] [Abstract][Full Text] [Related]
5. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.
Li G; Jiang H; Chang M; Xie H; Hu L
J Neurol Sci; 2011 May; 304(1-2):1-8. PubMed ID: 21377170
[TBL] [Abstract][Full Text] [Related]
6. HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes.
Noack M; Leyk J; Richter-Landsberg C
Glia; 2014 Apr; 62(4):535-47. PubMed ID: 24464872
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase 6 interacts with the microtubule-associated protein tau.
Ding H; Dolan PJ; Johnson GV
J Neurochem; 2008 Sep; 106(5):2119-30. PubMed ID: 18636984
[TBL] [Abstract][Full Text] [Related]
8. Increased acetylation of Peroxiredoxin1 by HDAC6 inhibition leads to recovery of Aβ-induced impaired axonal transport.
Choi H; Kim HJ; Kim J; Kim S; Yang J; Lee W; Park Y; Hyeon SJ; Lee DS; Ryu H; Chung J; Mook-Jung I
Mol Neurodegener; 2017 Feb; 12(1):23. PubMed ID: 28241840
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease.
Wang XX; Xie F; Jia CC; Yan N; Zeng YL; Wu JD; Liu ZP
Eur J Med Chem; 2021 Dec; 225():113821. PubMed ID: 34517222
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HDAC3 reverses Alzheimer's disease-related pathologies in vitro and in the 3xTg-AD mouse model.
Janczura KJ; Volmar CH; Sartor GC; Rao SJ; Ricciardi NR; Lambert G; Brothers SP; Wahlestedt C
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):E11148-E11157. PubMed ID: 30397132
[TBL] [Abstract][Full Text] [Related]
11. An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.
Carlomagno Y; Chung DC; Yue M; Castanedes-Casey M; Madden BJ; Dunmore J; Tong J; DeTure M; Dickson DW; Petrucelli L; Cook C
J Biol Chem; 2017 Sep; 292(37):15277-15286. PubMed ID: 28760828
[TBL] [Abstract][Full Text] [Related]
12. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.
Haggarty SJ; Koeller KM; Wong JC; Grozinger CM; Schreiber SL
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4389-94. PubMed ID: 12677000
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP/PS1 Alzheimer's disease mouse model by regulating the expression of APP secretases.
Zhang M; Wang W; Ye Q; Fu Y; Li X; Yang K; Gao F; Zhou A; Wei Y; Tian S; Li S; Wei F; Shi W; Li WD
Alzheimers Res Ther; 2024 Jan; 16(1):15. PubMed ID: 38245771
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HDAC6 modifies tau inclusion body formation and impairs autophagic clearance.
Leyk J; Goldbaum O; Noack M; Richter-Landsberg C
J Mol Neurosci; 2015 Apr; 55(4):1031-46. PubMed ID: 25434725
[TBL] [Abstract][Full Text] [Related]
15. Acetylation as a major determinant to microtubule-dependent autophagy: Relevance to Alzheimer's and Parkinson disease pathology.
Esteves AR; Palma AM; Gomes R; Santos D; Silva DF; Cardoso SM
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):2008-2023. PubMed ID: 30572013
[TBL] [Abstract][Full Text] [Related]
16. A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice.
Onishi T; Maeda R; Terada M; Sato S; Fujii T; Ito M; Hashikami K; Kawamoto T; Tanaka M
Sci Rep; 2021 Jul; 11(1):15423. PubMed ID: 34326423
[TBL] [Abstract][Full Text] [Related]
17. Protopine promotes the proteasomal degradation of pathological tau in Alzheimer's disease models via HDAC6 inhibition.
Sreenivasmurthy SG; Iyaswamy A; Krishnamoorthi S; Senapati S; Malampati S; Zhu Z; Su CF; Liu J; Guan XJ; Tong BC; Cheung KH; Tan JQ; Lu JH; Durairajan SSK; Song JX; Li M
Phytomedicine; 2022 Feb; 96():153887. PubMed ID: 34936968
[TBL] [Abstract][Full Text] [Related]
18. Modulation of histone deacetylase 6 (HDAC6) nuclear import and tubulin deacetylase activity through acetylation.
Liu Y; Peng L; Seto E; Huang S; Qiu Y
J Biol Chem; 2012 Aug; 287(34):29168-74. PubMed ID: 22778253
[TBL] [Abstract][Full Text] [Related]
19. MeCP2 deficiency is associated with reduced levels of tubulin acetylation and can be restored using HDAC6 inhibitors.
Gold WA; Lacina TA; Cantrill LC; Christodoulou J
J Mol Med (Berl); 2015 Jan; 93(1):63-72. PubMed ID: 25209898
[TBL] [Abstract][Full Text] [Related]
20. First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer's Disease.
Santini A; Tassinari E; Poeta E; Loi M; Ciani E; Trazzi S; Piccarducci R; Daniele S; Martini C; Pagliarani B; Tarozzi A; Bersani M; Spyrakis F; Danková D; Olsen CA; Soldati R; Tumiatti V; Montanari S; De Simone A; Milelli A
ACS Chem Neurosci; 2024 Jun; 15(11):2099-2111. PubMed ID: 38747979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
